Difference between revisions of "Semuloparin (AVE-5026)"
Jump to navigation
Jump to search
Warner-admin (talk | contribs) m (Text replacement - "7 PubMed" to "7/ PubMed") |
Warner-admin (talk | contribs) |
||
| Line 9: | Line 9: | ||
==Also known as== | ==Also known as== | ||
| − | *'''Code name:''' | + | *'''Code name:''' AVE-5026 |
==References== | ==References== | ||
Revision as of 00:39, 29 July 2023
General information
Class/mechanism: Hemisynthetic ultra low molecular weight heparin (ULMWH), binds to antithrombin III, accelerating its activity and inhibiting factor Xa, factor IIa, and thrombin.[1][2]
Route: SC
Extravasation: n/a
Patient drug information
No information available.
Also known as
- Code name: AVE-5026
References
- ↑ Semuloparin (AVE5026) manufacturer's website
- ↑ Agnelli G, George DJ, Kakkar AK, Fisher W, Lassen MR, Mismetti P, Mouret P, Chaudhari U, Lawson F, Turpie AG; SAVE-ONCO Investigators. Semuloparin for thromboprophylaxis in patients receiving chemotherapy for cancer. N Engl J Med. 2012 Feb 16;366(7):601-9. link to original article PubMed